Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Improving Prediction of Metabolic Clearance Using Quantitative Extrapolation of Results Obtained From Human Hepatic Micropatterned Cocultures Model and by Considering the Impact of Albumin Binding.

Da-Silva F, Boulenc X, Vermet H, Compigne P, Gerbal-Chaloin S, Daujat-Chavanieu M, Klieber S, Poulin P.

J Pharm Sci. 2018 Jul;107(7):1957-1972. doi: 10.1016/j.xphs.2018.03.001. Epub 2018 Mar 7.

PMID:
29524447
2.

IMI - oral biopharmaceutics tools project - evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds.

Margolskee A, Darwich AS, Pepin X, Pathak SM, Bolger MB, Aarons L, Rostami-Hodjegan A, Angstenberger J, Graf F, Laplanche L, Müller T, Carlert S, Daga P, Murphy D, Tannergren C, Yasin M, Greschat-Schade S, Mück W, Muenster U, van der Mey D, Frank KJ, Lloyd R, Adriaenssen L, Bevernage J, De Zwart L, Swerts D, Tistaert C, Van Den Bergh A, Van Peer A, Beato S, Nguyen-Trung AT, Bennett J, McAllister M, Wong M, Zane P, Ollier C, Vicat P, Kolhmann M, Marker A, Brun P, Mazuir F, Beilles S, Venczel M, Boulenc X, Loos P, Lennernäs H, Abrahamsson B.

Eur J Pharm Sci. 2017 Jan 1;96:598-609. doi: 10.1016/j.ejps.2016.09.027. Epub 2016 Sep 23.

PMID:
27671970
3.

Evaluation of Normalization Methods To Predict CYP3A4 Induction in Six Fully Characterized Cryopreserved Human Hepatocyte Preparations and HepaRG Cells.

Vermet H, Raoust N, Ngo R, Esserméant L, Klieber S, Fabre G, Boulenc X.

Drug Metab Dispos. 2016 Jan;44(1):50-60. doi: 10.1124/dmd.115.065581. Epub 2015 Oct 14.

PMID:
26467767
4.

PBPK modeling of irbesartan: incorporation of hepatic uptake.

Chapy H, Klieber S, Brun P, Gerbal-Chaloin S, Boulenc X, Nicolas O.

Biopharm Drug Dispos. 2015 Nov;36(8):491-506. doi: 10.1002/bdd.1961. Epub 2015 Aug 3.

PMID:
26037524
5.

Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics.

Djebli N, Fabre D, Boulenc X, Fabre G, Sultan E, Hurbin F.

Drug Metab Dispos. 2015 Apr;43(4):510-22. doi: 10.1124/dmd.114.062596. Epub 2015 Jan 21.

PMID:
25609219
6.

CYP3A4-based drug-drug interaction: CYP3A4 substrates' pharmacokinetic properties and ketoconazole dose regimen effect.

Boulenc X, Nicolas O, Hermabessière S, Zobouyan I, Martin V, Donazzolo Y, Ollier C.

Eur J Drug Metab Pharmacokinet. 2016 Feb;41(1):45-54. doi: 10.1007/s13318-014-0235-4. Epub 2014 Nov 6.

PMID:
25374256
7.

Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development.

Boulenc X, Barberan O.

Drug Metabol Drug Interact. 2011;26(4):147-68. doi: 10.1515/DMDI.2011.031. Review.

PMID:
22149659
8.

Clopidogrel pharmacodynamics and pharmacokinetics in the fed and fasted state: a randomized crossover study of healthy men.

Hurbin F, Boulenc X, Daskalakis N, Farenc C, Taylor T, Bonneau D, Lacreta F, Cheng S, Sultan E.

J Clin Pharmacol. 2012 Oct;52(10):1506-15. Epub 2011 Nov 29.

PMID:
22128201
9.

Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite.

Boulenc X, Djebli N, Shi J, Perrin L, Brian W, Van Horn R, Hurbin F.

Drug Metab Dispos. 2012 Jan;40(1):187-97. doi: 10.1124/dmd.111.040394. Epub 2011 Oct 17.

PMID:
22004687
10.

Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.

Turpault S, Brian W, Van Horn R, Santoni A, Poitiers F, Donazzolo Y, Boulenc X.

Br J Clin Pharmacol. 2009 Dec;68(6):928-35. doi: 10.1111/j.1365-2125.2009.03548.x.

11.

Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis.

Ragueneau-Majlessi I, Boulenc X, Rauch C, Hachad H, Levy RH.

Curr Drug Metab. 2007 Dec;8(8):810-4.

PMID:
18220561
12.

Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line.

Grès MC, Julian B, Bourrié M, Meunier V, Roques C, Berger M, Boulenc X, Berger Y, Fabre G.

Pharm Res. 1998 May;15(5):726-33.

PMID:
9619781
14.

Importance of the paracellular pathway for the transport of a new bisphosphonate using the human CACO-2 monolayers model.

Boulenc X, Marti E, Joyeux H, Roques C, Berger Y, Fabre G.

Biochem Pharmacol. 1993 Nov 2;46(9):1591-600.

PMID:
8240416
15.

Regulation of cytochrome P450IA1 gene expression in a human intestinal cell line, Caco-2.

Boulenc X, Bourrie M, Fabre I, Roque C, Joyeux H, Berger Y, Fabre G.

J Pharmacol Exp Ther. 1992 Dec;263(3):1471-8.

PMID:
1469646

Supplemental Content

Loading ...
Support Center